Enzymotec is pleased to announce the publication of a manuscript describing the promising results obtained in its pre-clinical study conducted at Tel-Aviv University, Israel (Vaisman N, Pelled D, Prog Neuro-Psychopharmacol Biol Psychiatry (2009), doi:10.1016/j.pnpbp.2009.04.021).
The manuscript describes the results of a pre-clinical study which assessed the effect of phosphatidylserine (PS) conjugated to omega-3 long-chain polyunsaturated fatty acids (PS-Omega3) on rats' DHA bioavailability and cognitive performance. The study results showed that rats fed with PS-Omega3 conjugate exceeded the beneficial effects demonstrated by conventional PS (soy derived PS) with or without fish oil in attenuating memory impairment as well as in enriching brain's DHA levels.
"We show for the first time that DHA on the backbone of phospholipids, rather than triglycerides, has a preferable incorporation into brain tissues and consequently a significant improvement in cognitive abilities" says Dr. Yael Richter, head of Enzymotec cognitive research group.
"Enzymotec is continuously investing financial and human recourses in order to support the clinical efficacy of company's products. This pre-clinical study is just one among several studies currently conducted by Enzymotec" concludes Yael.
Enzymotec is a developer and manufacturer of innovative, lipid-based bio-functional solutions for orthomolecular medicine, dietary supplements and advanced infant nutrition. Key products are: Sharp-PS® line of products- phosphatidylserine based ingredients for cognitive improvement, InFat® - structured fat for infant formulas, Sharp GPC™ for optimal mental performance CardiaBeat® - offering broad health effect to reduce CVD risks and Krill Oil+™.